Year 2021 (55)

Edition nr. 4


Erlotinib

Erlotinib (Tarceva®) was the first EGFR tyrokinase inhibitor to be authorized for the treatment of non-small-cell lung carcinoma (NSCLC). It enabled outpatient treatment, and has a more favourable adverse effects profile than the existing chemoth ...

In short Read article


Vaccines for COVID-19: vector vaccines

Vector vaccines are produced using a relatively new technology which, among other things,  involves genetic techniques. After the genome of a new virus has been sequenced, this technology enables the rapid production of an effective vaccine. In v ...

In short Read article